lewy body disease pipeline insight

DelveInsight’s, “Lewy Body Disease - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Lewy Body Disease  pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Geography Covered

• Global coverage

 

Lewy Body Disease: Understanding

Lewy Body Disease: Overview

Lewy Body Disease (LBD) is caused by the degeneration and death of nerve cells in the brain. The name comes from the presence of abnormal spherical structures, called Lewy bodies, which develop inside nerve cells. It is thought that these may contribute to the death of the brain cells. They are named after the doctor who first wrote about them. It is sometimes referred to as Diffuse Lewy Body Disease. At present there is no known cause of Lewy Body Disease, and no known risk factors have been identified. There is no evidence that it is an inherited disease. Symptoms such as depression and disturbing hallucinations can usually be reduced by medication. However, medications to relieve hallucinations may increase muscle tremors and stiffness. Conversely, anti-Parkinson drugs may make hallucinations worse. Other symptoms include movement disorders, poor regulation of body functions, cognitive problems, and trouble with sleep, varying attention, and depression.

These Lewy bodies are primarily found in the cerebral cortex and substantia nigra, regions critical for cognitive function and movement regulation. The pathology of LBD involves widespread neurodegeneration, leading to a progressive decline in cognitive abilities, motor dysfunction, and a range of neuropsychiatric symptoms, including visual hallucinations and fluctuating attention. The presence of Lewy bodies disrupts normal cellular function, impairs synaptic transmission, and ultimately results in neuronal death. The exact cause of alpha-synuclein aggregation remains unclear, but genetic, environmental, and age-related factors are believed to contribute to the disease process.

 

Diagnosing Lewy Body Disease (LBD) involves a multifaceted approach due to its overlapping symptoms with other neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. Clinicians rely on a combination of clinical assessment, patient history, and neurological examination to identify key features of LBD. Core diagnostic criteria include fluctuating cognitive function, visual hallucinations, and parkinsonian motor symptoms, such as bradykinesia, rigidity, and tremors.

There is no cure for Lewy body dementia, but many of the symptoms can improve with targeted treatments. Medications include Cholinesterase inhibitors these Alzheimer's disease medicines work by increasing the levels of chemical messengers in the brain, known as neurotransmitters, Parkinson's disease medicines. Medicines such as carbidopa-levodopa (Sinemet, Duopa, others) can help reduce rigid muscles and slow movement. Certain medicines can worsen memory. Therapies antipsychotic medicines can worsen Lewy body dementia symptoms. It might be helpful to first try other approaches, such as: Tolerating the behavior. Some people with Lewy body dementia aren't distressed by the hallucinations. Modifying the environment and reducing clutter and noise can make it easier for someone with dementia to function and lastly by creating daily routines and keeping tasks simple break tasks into easier steps and focus on successes, not failures. Structure and routine during the day can be less confusing.

 

“Lewy Body Disease - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Lewy Body Disease pipeline landscape is provided which includes the disease overview and Lewy Body Disease treatment guidelines. The assessment part of the report embraces, in depth Lewy Body Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lewy Body Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Lewy Body Disease R&D. The therapies under development are focused on novel approaches to treat/improve Lewy Body Disease.

 

Lewy Body Disease Emerging Drugs Chapters

This segment of the Lewy Body Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Lewy Body Disease Emerging Drugs

• LY3154207: Eli Lilly and Company

Mevidalen (LY3154207) is a selective and orally active D1-positive allosteric modulator with >1000-fold selectivity for the human D1 receptor over other tested targets. Mevidalen increases the extracellular level of acetylcholine in the prefrontal cortex and enhances the affinity of dopamine for the D1 receptor. This amplifies the responses to endogenous and exogenous dopamine, which may improve motor and cognitive symptoms of Parkinson Disease and Lewy body dementias as well as sleepiness, mood, and apathy.

 

• CT1812: Cognition Therapeutics

Zervimesine (CT1812) is an investigational oral, once-daily pill being developed for the treatment of CNS diseases such as Alzheimer’s disease and dementia with Lewy bodies (DLB). While these diseases have different symptoms, both are associated with the buildup of certain proteins in the brain – Aβ and ɑ-synuclein. As these proteins bind to neurons, they can damage and ultimately destroy the neurons. This results in a progressive loss in a person’s ability to learn, recall memories, move efficiently, or communicate. These diseases progress relentlessly and ultimately result in death. If zervimesine can interrupt the toxic effects of these proteins, it may be able to slow progression of disease and improve the lives of those suffering from Alzheimer’s and DLB.

 

• Neflamapimod: CervoMed

Neflamapimod is an investigational, orally administered small molecule brain penetrant drug that inhibits alpha isoform of the p38MAP kinase. In preclinical studies, neflamapimod reversed synaptic dysfunction, including and particularly within the part of the brain most impacted in DLB – the basal forebrain cholinergic system. In Phase I and Phase II clinical studies involving more than 400 participants, neflamapimod has been shown to be generally well tolerated. Results from the AscenD-LB Phase IIa clinical study demonstrated that neflamapimod improved dementia severity (assessed by CDR-SB) compared to placebo and improved functional mobility (assessed by TUG test) compared to placebo. At the highest dose evaluated, neflamapimod also improved results on a cognitive test battery. The treatment response in AscenD-LB in the participants who did not have AD co-pathology (as assessed by a blood biomarker, plasma ptau181) was substantial (effect size > 0.7) and greater than the overall study population. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Lewy body disease.

Further product details are provided in the report…….

 

Lewy Body Disease: Therapeutic Assessment

This segment of the report provides insights about the different Lewy Body Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Lewy Body Disease

There are approx. 10+ key companies which are developing the therapies for Lewy Body Disease. The companies which have their Lewy Body Disease drug candidates in the most advanced stage, i.e. Phase II include Eli Lilly and Company.

 

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Lewy Body Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
•  Subcutaneous
• Topical
• Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Lewy Body Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Lewy Body Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lewy Body Disease drugs.

 

Lewy Body Disease Report Insights

• Lewy Body Disease  Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Lewy Body Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lewy Body Disease drugs?
• How many Lewy Body Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lewy Body Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lewy Body Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lewy Body Disease and their status?
• What are the key designations that have been granted to the emerging drugs?